WILMINGTON, Del., May 02, 2025--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose ...
WILMINGTON, Del.--(BUSINESS WIRE)--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI ...
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...
AstraZeneca (NASDAQ:AZN) has initiated a Phase 3 study to evaluate the use of inhaled triple-combination therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with ...
After AstraZeneca’s fast-growing respiratory biologic Fasenra failed to move the needle in a COPD trial, hopes were directed to its three-in-one inhaler Breztri. But the potential challenger to ...
With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.
Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan. In ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback